Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Mar 4:16:1476563.
doi: 10.3389/fimmu.2025.1476563. eCollection 2025.

Ceftriaxone-induced immune hemolytic anemia: a case report

Affiliations
Case Reports

Ceftriaxone-induced immune hemolytic anemia: a case report

Li Wang et al. Front Immunol. .

Abstract

Background: Drug-induced immune hemolytic anemia (DIIHA) is a rare but serious disease associated with various antibiotics, which is often misdiagnosed. DIIHA often leads to adverse outcomes, including organ failure and even death. Ceftriaxone is one of the most common drugs that cause DIIHA. This study reports a case of ceftriaxone-induced DIIHA.

Case description: A 5-year-old patient diagnosed with community-acquired pneumonia developed a rash on the 5th day of anti-infective treatment with cefazoxime and azithromycin, followed by a rapid decline in hemoglobin levels and the presence of hemoglobin in the urine (hemoglobinuria). Laboratory analysis showed a positive Coombs' test for the patient. The rash and hematuria subsided after cefazoxime and azithromycin were stopped and symptomatic treatment such as methylprednisolone intravenous infusion, sodium bicarbonate-alkalized urine, enoxaparin sodium anticoagulation, and antiallergic therapy. 5 days later, the child was treated with ceftriaxone for anti-infective therapy because the pneumonia was not healed. During the treatment, the patient suddenly developed itching all over the body, pale face, slightly fast breathing, vomiting, abdominal pain, and low back pain. Immediate cessation of ceftriaxone sodium infusion, continuous nasal catheter oxygen inhalation, normal saline dilatation, and meprednisolone anti-inflammatory and symptomatic treatment of cetirizine were performed. On the evening of the same day, the patient presented with symptoms of wine-colored urine. Laboratory analysis indicated severe anemia and persistent hemolysis, which was considered to autoimmune hemolytic anemia caused by ceftriaxone. After three transfusions and plasma exchange, the patient improved and was discharged from the hospital. One month later, there were no obvious abnormalities in urine analysis, blood routine analysis, reticulocyte analysis, and liver function test.

Conclusion: Understanding the patient's medical history can provide critical information for the diagnosis of DIIHA, and effective management of DIIHA includes immediate discontinuation of suspected drugs, transfusion support, plasma exchange, and symptomatic medication.

Keywords: Coombs’ test; ceftriaxone; decreased hemoglobin; drug-induced immune hemolytic anemia; hemolysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Hb of patients for different days after admission.

Similar articles

Cited by

References

    1. Hansen DL, Frederiksen H. A leap in recognizing drug-induced immune hemolytic anemia. Blood Adv. (2024) 8:815–6. doi: 10.1182/bloodadvances.2023011842 - DOI - PMC - PubMed
    1. Barcellini W, Fattizzo B. Novel pharmacotherapy for drug-induced immune hemolytic anemia. Expert Opin Pharmacother. (2023) 24:1927–31. doi: 10.1080/14656566.2023.2291075 - DOI - PubMed
    1. Lou C, Liu M, Ma T, Yang L, Long D, Li J, et al. . Case report: Decreased hemoglobin and multiple organ failure caused by ceftizoxime-induced immune hemolytic anemia in a Chinese patient with Malignant rectal cancer. Front Immunol. (2024) 15:1390082. doi: 10.3389/fimmu.2024.1390082 - DOI - PMC - PubMed
    1. Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A, et al. . Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. (2017) 177:208–20. doi: 10.1111/bjh.2017.177.issue-2 - DOI - PubMed
    1. Maquet J, Lafaurie M, Michel M, Lapeyre-Mestre M, Moulis G. Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort study. Blood Adv. (2024) 8:817–26. doi: 10.1182/bloodadvances.2023009801 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources